Hepatitis B prevalence in an unregistered prenatal population. Implications for neonatal therapy

JAMA. 1991 Nov 27;266(20):2852-5.

Abstract

Study objective: To evaluate the risk and associated cofactors for hepatitis B infection in inner-city pregnant women not registered for prenatal care.

Design: Fifteen-month survey of 208 patients not registered for prenatal care, compared with 1555 women registered for prenatal care during the same period.

Setting: An urban university hospital prenatal clinic and labor unit.

Results: Unregistered patients had a significantly higher rate of hepatitis B surface antigen positivity than patients who had registered with the clinic (6.7% vs 0.8%; P less than .0001). Unregistered patients with positive results of urine drug screening (46%) had a relative risk for seropositivity of 29.2%, compared with registered patients who did not have histories of illicit drug use (95% confidence interval, 25.9% to 32.4%), while registered patients with past histories of drug use had a relative risk of 6.7%, compared with the reference group that did not have histories of drug use (95% confidence interval, 1.8% to 24.0%).

Conclusions: Among inner-city pregnant women not registered for prenatal care, a positive result of urine drug screening is a rapidly available marker for increased risk of hepatitis B surface antigen positivity. Infants born to unregistered women with positive results of urine drug screening before maternal hepatitis B surface antigen results are available may warrant empiric initiation of hepatitis B virus-specific prophylaxis.

Publication types

  • Comparative Study

MeSH terms

  • Female
  • Hepatitis B / epidemiology*
  • Hepatitis B / ethnology
  • Hepatitis B / immunology
  • Hepatitis B / prevention & control
  • Hepatitis B Surface Antigens / analysis
  • Hepatitis B Vaccines
  • Humans
  • Philadelphia / epidemiology
  • Pregnancy
  • Pregnancy Complications, Infectious / epidemiology*
  • Pregnancy Complications, Infectious / ethnology
  • Pregnancy Complications, Infectious / prevention & control
  • Prenatal Care / statistics & numerical data*
  • Risk Factors
  • Vaccines, Synthetic
  • Viral Hepatitis Vaccines

Substances

  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines
  • Vaccines, Synthetic
  • Viral Hepatitis Vaccines